Pressurized container containing haemostatic paste

Information

  • Patent Grant
  • 11109849
  • Patent Number
    11,109,849
  • Date Filed
    Tuesday, March 5, 2013
    11 years ago
  • Date Issued
    Tuesday, September 7, 2021
    3 years ago
Abstract
The present invention relates to a container adapted to dispense its content under pressure. The container of the present invention consists of two separate compartments separated from one another by a slidable piston. The container of the present invention contains a haemostatic paste.
Description

This application is the U.S. National Stage of International Application No. PCT/DK2013/050054, filed Mar. 5, 2013, which designates the U.S., published in English, and claims priority under 35 U.S.C. §§ 119 or 365(c) to Denmark Application No. PA 2012 70099 filed Mar. 6, 2012.


FIELD OF INVENTION

The present invention relates to a container adapted to dispense its content under pressure. The container of the present invention consists of two separate compartments separated from one another by a slidable piston. The container of the present invention contains a haemostatic paste.


BACKGROUND OF INVENTION

The use of haemostatic agents provides for control of bleeding in surgical procedures. Haemostatic agents, supplement pressure, ligature and other conventional methods of controlling capillary, venous and arterial bleeding are known.


In the field of haemostatic control different devices for application of haemostatic agents are currently on the market.


One such product (Surgiflo®) is a pre-filled syringe applied with an applicator tip. The syringe contains the haemostatic agent in paste form in a volume which allows suitable mixing of the haemostatic agent with any further agent, such as water, saline and thrombin, within the containment unit. Upon manual mixing of the haemostatic agent and the further agent a haemostatic paste is formed within the syringe.


Only after such a haemostatic paste has been formed the user may then apply the paste to the site of bleeding.


The design of the syringe leads to the need for applying manual pressure on the plunger located within the containment unit from behind leading to loss of some control with the direction in which the applicator tip is pointed, i.e. aiming correctly at the site of bleeding is made more difficult.


Due to the viscosity of the haemostatic paste formed in the containment unit after mixing, the user has to apply considerable force to the end of the plunger in order to empty the haemostatic paste out of the containment unit onto a site of bleeding.


Because such a relative high force is needed the precision in applying the product is limited and the device has limited user-friendliness.


Accordingly there is a need for a device in the field of haemostatic control which in one easy-to-use-device provides a haemostatic paste to a site of bleeding directly from a sterile container with great precision and ease for the user.


A vast range of materials are routinely dispensed from pressurized containers. Special containers exists which are able to keep the product out of contact with the propellant. There are generally speaking two types of these containers, “the collapsible bag” type and the “piston” type. The “collapsible bag” type comprises a collapsible bag arrangement where the product is held in a flexible bag secured to the neck of the container with an outlet valve. The propellant is held between the bag and the container wall. Under pressure the bag collapses and extrudes the product from the outlet valve. Filling of the bags is performed under high pressure through the valve which induces phase-separation in paste products. Additionally, filling of the product through the valve makes it possible to have residual paste maintained in the opening of the valve after the filling is completed. This residual paste would function as a plug of paste that would have to be removed prior to the use of the device. Also the opening of the valve is restricted which makes filling and especially emptying of the can difficult


In the “piston” type the container is divided into two chambers by an internal piston, and product and propellant is held separately from each other with this piston. Under pressure of the propellant the piston forces the product from the container through a valve.


The “piston” type containers are usually used for product in liquid, fluid, paste and plastic form, such as foodstuffs (mayonnaise, whipped cream etc.), cosmetics (dentifrice, shaving cream etc.), pharmaceuticals (ointment, rat poison etc.) and chemical products (sealant, adhesive etc.).


SUMMARY OF INVENTION

The invention relates to a device for dispensing a haemostatic paste from a container under pressure having an interior including a product compartment and a propellant compartment separated from one another and a slidable piston separating the product compartment from the propellant compartment.


This device provides haemostatic paste which may be administered with great precision and by use of a minimal amount of force. Preferably, the haemostatic paste is ready-to-use. In this context “ready-to-use” is intended to mean a paste that can be applied directly from the pressurized container to a subject. This does not exclude the possibility that further ingredients are mixed into the haemostatic paste after it has been expelled from the pressurized container.


DETAILED DESCRIPTION OF THE INVENTION

In the field of haemostatic control it would be beneficial to be able to provide a haemostatic paste to a site of bleeding directly from a pressurized container with great precision and by use of a minimal amount of force by the user. With haemostatic pastes it is necessary to store the paste separately from the propellant intended to keep the paste under pressure. To do this, the paste is kept separate from the propellant by means of a piston capable of sliding in sealed contact against the interior surface of the body of the container.


In order to obtain the required advantage of the piston, such a system requires that throughout the life of the device, that is from the first use to the last use, the pressure exerted by the propellant must be higher than the vapour pressure of the product.


The invention relates to a device for dispensing a haemostatic paste from a container under pressure.


In this way a sterile and facile administration of haemostatic paste is provided. Surgeons state that the present syringe type applicators require considerable force to apply, which compromises precision. This is overcome by the present invention which makes administration of the haemostatic paste easier by use of a propellant as driving force. The device of the invention is furthermore designed such that it can be pointed in all directions whilst complete emptying of the container is still possible. This is of high importance during a surgical procedure where the bleeding site may be located in difficult to reach places. As stated above previous products typically require considerable manual force for application to a bleeding site and the precise application of the haemostatic agent is difficult and requires some strength of the surgeon.


The device of the present invention comprises a container having an interior including a product compartment and a propellant compartment separated from one another, said container having a first end with a haemostatic paste outlet extending from the product compartment, said outlet being openable and closable. A valve is located in communication with the first end of the product compartment. The valve may be positioned in connection with the haemostatic paste outlet to allow for flow of the haemostatic paste through the haemostatic paste outlet to the exterior of the device. A slidable piston is separating the product compartment from the propellant compartment.


The piston may comprise a primary piston having a primary wall-engaging skirt and a secondary piston having a secondary wall-engaging skirt and between said primary and secondary pistons an interposed deformable sealant material is located.


Under pressure said deformable material may be compressed between the primary and secondary pistons and urged against the container wall to form a seal. To ensure this function the primary piston is preferably in frictional engagement with the wall of the contained and the secondary piston is preferably in loose fit thus to encourage compression of the interposed deformable sealant material. This arrangement of the primary and secondary pistons make it possible to provide an efficient seal between the propellant chamber and the product chamber ensuring that the propellant is not mixed with the product at any time.


The deformable sealant material may be any liquid or semi-solid material which is chemically compatible with the materials it will come into contact with in use. Water-based materials such as aqueous gels of alginic materials are suitable, as are many organic and mineral oils, greases and waxes. The sealant material may in one embodiment be selected from the group consisting of: ethylene glycol, diethylene glycol, butylene glycol, amylene glycol, glycerol, polyglycerin, glycerin, polyvinyl alcohol, silicone, acrylic resin.


In one embodiment the deformable sealant material is a gel. In a more preferred embodiment the deformable sealant is an aqueous gel.


The valve used with the present invention is preferably arranged to allow easy flow of the haemostatic paste through the haemostatic paste outlet and to allow the paste to be dispensed to exit via the valve. As the haemostatic pastes are viscous pastes the valve may be arranged with optimized fluid passage for example by having large inlet and/or out let openings, smooth surfaces and/or a passage way through which the paste may flow without being limited by bends, protrusions etc.


In some advantageous embodiments the valve is furthermore fitted with an exchangeable, bendable and/or cutable long tip of the known type. For example such tips are used in conjunction with Surgiflo® haemostatic paste applicators.


The exchangeable tip can be selected in order to allow administration of the haemostatic paste in hard to reach areas, to allow passage of a fluid with a specific viscosity and/or administer fluid at a specific flow rate.


If a cutable long tip is provided the tip can be cut to a desired length with respect to given circumstances of the administration such as viscosity of fluid (haemostatic paste), administration area etc. If the long tip is at least partly conical the tip can be cut to provide a specific diameter to the exit opening of the tip.


Alternatively a bendable tip is provided which holds its shape after being bent and preferably will not kink when being bend. The bendable tip can be bendable in all directions.


Thus, the user may shape the tip to be optimized for administration of a specific fluid and/or optimized for administration of the fluid in hard to reach areas. For example the exchangeable tip may be bent to have an optimized curvature and a cut to have a desired length by the user.


The tip is in one embodiment between 5-20 cm long, such as 10-20 cm long, such as 15-20 cm long.


In one embodiment the tip is not bendable.


This need for a controlled hold and movement is enhanced when a long tip is use such as the bendable tips mentioned above. This is due to the fact that any movements of the users hands may be enhanced at a distant tip.


Preferably the device comprises a movable actuator coupled to the valving member so that actuating movement of the actuator actuates the valving member to the open position. For example the actuator may be of a form wherein a handle part of the actuator is positioned along the side of the container in a distance and angle from the container making it easy to reach and press by the user preferably with a minimal change of hand position.


Further, the actuator may preferably be arranged to require a minimum of force by the user in order to actuate the valve and administer the haemostatic paste. This can for example be achieved by an actuator arrangement with a hinged lever arm transferring the force applied by the user to the movable valving member. When less force is required to actuate the valve the user is more likely to have a steady hand and is less likely to make any intentional movements with the device ensuring a reliable and optimal administration of the haemostatic paste.


The pressure in the propellant chamber is in one embodiment in the range of 100-500 kPa at room temperature, more preferably in the range of 200-500 kPa, such as 300-500 kPa, more preferably 400-500 kPa. In another embodiment the pressure in the propellant chamber is in the range 100-400 kPa at room temperature, such as 100-300 kPa, more preferably 100-200 kPa.


The propellant may be selected from the group consisting of nitrogen, oxygen, compressed air, butane, propane, chlorofluorocarbon, fluorocarbon and dimethyl ether. In a preferred embodiment the propellant is nitrogen, oxygen or compressed air.


A brief description of the preferred method of filing and assembly of the device is described in Example 1.


The haemostatic paste of the present invention has a viscosity in the range of 700-4.000 Pa·s at room temperature, such as between 1.000-4.000 Pa·s, for example 1.200-4.000 Pa·s, such as 1.400-4.000 Pa·s, for example 1.600-4.000 Pa·s, such as 1.800-4.000 Pa·s, for example 2.000-4.000 Pa·s, such as 2.200-4.000 Pa·s, for example 2.400-4.000 Pa·s, such as 2.600-4.000 Pa·s, for example 2.800-4.000 Pa·s, such as 3.000-4.000 Pa·s, for example 3.200-4.000 Pa·s, such as 3.400-4.000 Pa·s, for example 3.600-4.000 Pa·s, such as 3.800-4000 Pa·s


In another embodiment of the present invention, the haemostatic paste of the present invention has a viscosity in the range 700-4.000 Pa·s, for example 700-3.800 Pa·s, such as 700-3.600 Pa·s, for example 700-3.400 Pa·s, such as 700-3.200 Pa·s, for example 700-3.000 Pa·s, such as 700-2.800 Pa·s, for example 700-2.600 Pa·s, such as 700-2.400 Pa·s, for example 700-2.200 Pa·s, such as 700-2.000 Pa·s, for example 700-1.800 Pa·s, such as 700-1.600 Pa·s, for example 700-1.400 Pa·s, such as 700-1.200 Pa·s, for example 700-1.000 Pa·s, such as 700-900 Pa·s, for example 700-800 Pa·s.


The haemostatic paste of the present invention may comprise 10-25% v/v of gelatine or collagen and a suitable liquid. The suitable liquid may be selected from the group consisting of: sterile water, sterile saline and sterile PBS buffer. The haemostatic paste may be combined with another active ingredient. An appropriate amount of another active agent may be added to the haemostatic paste. Such another active agent may be selected from the group consisting of: germicidal agent, preservative, antimicrobial agents, coagulation factors, antifibrinolytic agents, surfactants, growth factors to promote healing, calcium ions to aid coagulation, adrenaline or other substances capable of constricting blood vessels.


Specific examples of coagulation factors include coagulation factors selected from the group consisting of thrombin, fibrinogen, aprotinin, fibronectin, factor XIII, factor VII, factor VIII, and combinations thereof. Such compounds may be of any mammalian origin, such as of porcine or human origin, or may be obtained by recombinant means by methods well-known to the skilled person. It will be understood that gelatine and collagen are not considered as being coagulation factors.


Antifibrinolytic agents may be selected from the group consisting of tranexamic acid, ε-aminocaproic acid, aprotinin, pepstatin, leupeptin, antipain, chymostatin, gabexate, and mixtures thereof. If present, the antifibrinolytic agent is preferably tranexamic acid.


Antimicrobial agents may be selected from bactericidal or bacteriostatic agents, such as antibiotics and sulphonamides, antiviral compounds, antimycotic agents and anti-infectives.


Surfactants may be selected from the group consisting of anionic surfactants, cationic surfactants, non-ionic surfactants and surface active biological modifiers.


However, in a preferred embodiment of the invention, the composition does not contain such another active agent, i.e. said composition does not contain germicidal agent, coagulation factors, anti-fibrinolytic agents, surfactants, antimicrobial agents, preservative, growth factors, calcium ions, adrenaline and/or other substances capable of constricting blood vessels


All ingredients of the haemostatic paste should be able to tolerate sterilization by radiation and still keep the activity.


Within the device of the present invention, the haemostatic paste preferably has a minimum shelf-life of two years at room temperature.


In use, the valve is opened releasing the internal pressure, the propellant in the propellant chamber expands thereby forcing the secondary piston into even closer contact with the sealant which is urged outward against the container wall. The primary piston advances and extrudes the product from the valve.


It is preferred that the primary and secondary piston is preferably made of a plastic material selected from the group consisting of Polyethylene (HDPE), Polystyrene, Akrylnitril-butadien-styren (ABS), polyamide (PA), Polypropylene, and Poly Vinyl Chloride (PVC). Preferably the primary and secondary piston is made of HDPE.


It is preferred that the container is made of aluminium coated on the inside with a coating. Such a coating may be selected from the group consisting of FDA approved coatings for example, but not limited to PPG2497-303/A (PPG Industries Lackfabrik GmbH), PPG2956-401/A (PPG Industries Lackfabrik GmbH) and J3121 (Valspar).


The valve of the device may be fitted with an appropriate actuator. The pressure needed to be exerted by the user on the actuator in order to empty the device may vary with different actuator types.


The device and all its components are preferably made of materials which can withstand sterilization by gamma radiation or beta radiation. Said sterilization is in one embodiment performed at 10-50 kGy, more preferably at 10-40 kGy, such as 10-30 kGy, more preferably 10-20 kGy. In another embodiment the sterilization is performed at 10-50 kGy, such at 20-50 kGy, more preferably 30-50 kGy, such as 40-50 kGy. In a preferred embodiment the sterilization is performed at 25-30 kGy.


The device of the present invention is preferably completely air and light tight. After having subjected the device to sterilization by radiation the haemostatic paste present in the product chamber is sterile and will remain so until use.


The present disclosure includes a method of providing a haemostatic paste, filling the haemostatic paste into the product compartment through the top of the open container, attaching a valve to the open end of the container, securely sealing the valve to the container by crimping of the valve body around the neck of the container top, filling the propellant compartment under pressure with a suitable propellant through the opening in the propellant compartment, and sealing the propellant compartment by insertion of a plug into the opening in the propellant compartment. The method further provides that the device is sterilised using radiation, preferably wherein the device is filled with haemostatic paste and propellant prior to sterilization. The type of sterilization can be gamma or beta radiation.


In the following the invention is described in further detail with reference to the drawings. However, all drawings are exemplary and are not to be construed as limiting to the invention.





DESCRIPTION OF DRAWINGS


FIG. 1 shows the overall design of the device of the invention,



FIG. 2 shows a preferred embodiment of the piston, and



FIG. 3 shows an embodiment of an actuator used with the present invention.





Referring to FIGS. 1 and 2, the device consists of an elongate cylindrical container 1 (which may be an extruded or seamed can) having a top 2 and inturned domed base 3, the top having a neck 4 and fitted therein a valved outlet extrusion valve 5.


Within the container 1 there are, located serially from top to bottom, a primary piston 6, a secondary piston 7 and a membrane partition 8. Located between pistons 6 and 7 there is a mass of deformable sealant material 9. These parts divide the internal volume of the container into a chamber 10 for the haemostatic paste to be dispensed and a chamber 11 for propellant. The presence of the membrane 8 is optional but, when present, it forms with the base 3 a propellant compartment 12. The base 3 has a generally central hole for introduction of propellant during filling after which it is closed by a plug 13.


The crown of the primary piston 6 is shaped to conform generally to the internal configuration of the container top and internal parts of the valve 5 so as to maximise the amount of product which can be expelled by the piston.


The base 3 of the container is domed and has a generally central hole for introduction of propellant during filing after which it is closed by a plug 13. Said hole for filling of propellant can accordingly be opened and closed.



FIG. 3 shows an embodiment of a movable actuator 4 used with the present invention. The actuator comprises a lever arm 15 connected to the haemostatic paste outlet of the device 16 by hinge 17 and a lever handle 18 extending from the lever arm 15 in an angle of approximately 90°. In the shown configuration the lever handle 18 is pressed towards the container 1 by a force indicated by arrow F and the valve is hereby opened allowing paste to pass from the inside of the container 1, through the valve and out through a tip 19. The force is provided by the grip of the user (not shown).


When the force is released by the user, the lever arm 15 and handle 18 will move towards a relaxed state wherein the valve is closed. The movement of the lever handle 18 towards the relaxed position is indicated by arrow R.


When the lever handle 18 is pressed by the user i.e. when the force F is applied by the user to open the valve, the lever handle is brought to a position in which it is parallel to or close to parallel to the longitudinal direction of the container. When the force is relaxed the handle moves back along the direction R. Thus, when the valve is closed the lever handle is relatively close to the container wall and is positioned in an angle which enables the user to easily change grip from holding around the container with all fingers to a grip holding around the lever handle with one or more fingers in order to apply the force F to actuate (i.e. open) the valve and administer the haemostatic paste until the force F is released. The tip 19 shown in FIG. 3 is slightly conical at towards the distal end 20 of the tip.


EXAMPLES
Example 1

Preparation of the Haemostatic Paste and Filling of the Device.


Cross-linked gelatine powder is mixed with a liquid such that the powder is fully wetted. The paste is filled into the device of the invention through the top of the open container into the product compartment. In this way the product may be filled into the product compartment without the use of valves and without being under pressure. The container is closed by attaching the valve body to the container. The valve is securely sealed to the container by crimping of the valve body. Once the valve is sealed to the container the propellant is filled into the propellant compartment under pressure through the opening in the propellant compartment. The propellant compartment is then sealed by a plug, such as a rubber stopper.

Claims
  • 1. A sterile device for storing and dispensing a sterilized and ready-to-use haemostatic paste under pressure, comprising: a) a sterilized container having an interior including a product compartment and a propellant compartment separated from one another, said container having a first end with a haemostatic paste outlet extending from the product compartment, said outlet being openable and closable;b) a valve in communication with the first end of the product compartment;c) a sterilized and ready-to-use haemostatic paste comprising 10-25% v/v of gelatin or collagen, a suitable liquid and optionally one or more preservatives contained in the product compartment, wherein the haemostatic paste has a minimum shelf-life of two years at room temperature;d) a propellant provided in the propellant compartment; ande) a slidable piston separating the product compartment from the propellant compartment.
  • 2. The device of claim 1, wherein said piston comprises a primary piston having a primary wall-engaging skirt, a secondary piston having a secondary wall-engaging skirt and between said primary and secondary pistons an interposed deformable sealant material.
  • 3. The device of claim 2, whereby under pressure said deformable material is compressed between the pistons and urged against the container wall to form a seal.
  • 4. The device according to claim 2, wherein the primary piston is in frictional engagement with the wall and the secondary piston is in loose fit thus to encourage compression of the interposed deformable sealant material.
  • 5. The device according to claim 2, wherein the deformable sealant material is a gel.
  • 6. The device according to claim 2, wherein the deformable sealant is an aqueous gel.
  • 7. The device according to claim 1, wherein the propellant is selected from the group consisting of: nitrogen, oxygen, compressed air, butane, propane, chlorofluorocarbon, fluorocarbon and dimethyl ether.
  • 8. The device according to claim 1, wherein said propellant chamber also contains a propellant inlet, said inlet being openable and closable.
  • 9. The device according to claim 1, wherein the pressure in the propellant compartment is 100-500 kPa at room temperature.
  • 10. The device according to claim 1, wherein the haemostatic paste has a viscosity in the range of 500-6000 Pa·s at room temperature.
  • 11. The device of claim 1, wherein the valve comprises a movable valving member configured to be moved from a closed position to an open position to enable flow of the haemostatic paste through a haemostatic paste outlet of the device.
  • 12. The device of claim 11, wherein the valve is made of a plastic material selected from the group consisting of: Polyethylene (HDPE), Polystyrene, Acrylonitrile-butadiene-styrene (ABS), polyamide (PA), Polypropylene, and Poly Vinyl Chloride (PVC).
  • 13. The device of claim 1, further comprising a movable actuator coupled to the valving member so that actuating movement of the actuator actuates the valving member to the open position.
  • 14. The device of claim 1, wherein the valve further includes a biasing member biasing the valving member toward the closed position.
  • 15. The device of claim 1, wherein the valve further comprises a seal cooperating with the valving member to prevent flow of the haemostatic paste from the valve when the valving member is in the closed position.
  • 16. The device of claim 1, wherein the container is made of metal or plastic.
  • 17. The device of claim 16, wherein the container is made of aluminium.
  • 18. The device of claim 1, wherein the container is coated with a FDA approved coating selected from the group consisting of: PPG2497-303/A, PPG2956-401/A and J3121.
  • 19. The device of claim 1, wherein the product compartment of the container has a volume ranging from 5-250 ml.
  • 20. The device of claim 1, wherein the propellant compartment of the container has a volume ranging from 5-250 ml.
  • 21. A method of applying the haemostatic paste to a site of bleeding comprising: a) providing the device of claim 1,b) attaching a bendable or non-bendable and/or cutable tip to the device,c) actuating the valve to dispense the haemostatic paste from the device, andd) directing the dispensed haemostatic paste to the site of bleeding.
  • 22. A method of making the device of claim 1, comprising: a) providing the device of claim 1,b) providing a haemostatic paste,c) filling the haemostatic paste into the product compartment through the top of the open container,d) attaching a valve to the open end of the container,e) securely sealing the valve to the container by crimping of the valve body around the neck of the container top,f) filling the propellant compartment under pressure with a suitable propellant through the opening in the propellant compartment, andg) sealing the propellant compartment by insertion of a plug into the opening in the propellant compartment.
  • 23. The method of claim 22, wherein the device is sterilised using radiation, preferably wherein the device is filled with haemostatic paste and propellant prior to sterilisation.
  • 24. The method of claim 23, wherein the sterilization is gamma or beta radiation.
  • 25. A sterile device for storing and dispensing a sterilized and ready-to-use haemostatic paste under pressure, comprising: a) a sterilized container having an interior including a sterile product compartment and a propellant compartment separated from one another, said container having a first end with a haemostatic paste outlet extending from the product compartment, said outlet being openable and closable;b) a valve in communication with the first end of the product compartment;c) a bendable or cuttable tip fitted to the valve;d) a sterilized and ready-to-use haemostatic paste contained in the sterile product compartment, wherein the haemostatic paste has a minimum shelf-life of two years at room temperature;e) a propellant provided in the propellant compartment; andf) a slidable piston separating the sterile product compartment from the propellant compartment.
Priority Claims (1)
Number Date Country Kind
PA 2012 70099 Mar 2012 DK national
PCT Information
Filing Document Filing Date Country Kind
PCT/DK2013/050054 3/5/2013 WO 00
Publishing Document Publishing Date Country Kind
WO2013/131520 9/12/2013 WO A
US Referenced Citations (410)
Number Name Date Kind
2465357 Correll et al. Mar 1949 A
2465860 Fleischmann Mar 1949 A
2507244 Correll May 1950 A
2558395 Studer Jun 1951 A
2899362 Sieger et al. Aug 1959 A
3089815 Kupelwieser et al. May 1963 A
3224434 Molomut et al. Dec 1965 A
3405712 Pierick Oct 1968 A
3514518 Charier-Vadrot May 1970 A
3608593 McCormick et al. Sep 1971 A
3678933 Moore et al. Jul 1972 A
3815580 Oster Jun 1974 A
3869539 Kring et al. Mar 1975 A
3892876 Hobday et al. Jul 1975 A
3930052 De Brou et al. Dec 1975 A
3946732 Hursham Mar 1976 A
4002173 Manning et al. Jan 1977 A
4006220 Gottlieb Feb 1977 A
4013078 Feild Mar 1977 A
4098728 Rosenblatt et al. Jul 1978 A
4107288 Oppenheim et al. Aug 1978 A
4124705 Rothman et al. Nov 1978 A
4160022 Delaney et al. Jul 1979 A
4164559 Miyata et al. Aug 1979 A
4179400 Tsao et al. Dec 1979 A
4194392 Lombard et al. Mar 1980 A
4208439 Hsu Jun 1980 A
4256877 Karlsson et al. Mar 1981 A
4265233 Sugitachi et al. May 1981 A
4280954 Yannas et al. Jul 1981 A
4291013 Wahlig et al. Sep 1981 A
4292972 Pawelchak et al. Oct 1981 A
4298598 Schwarz et al. Nov 1981 A
4300494 Graiff et al. Nov 1981 A
4320201 Berg et al. Mar 1982 A
4347234 Wahlig et al. Aug 1982 A
4362567 Schwarz et al. Dec 1982 A
4377572 Schwarz et al. Mar 1983 A
4416813 Ikeda et al. Nov 1983 A
4424208 Wallace et al. Jan 1984 A
4453939 Zimmerman Jun 1984 A
4482386 Wittwer et al. Nov 1984 A
4492305 Avery Jan 1985 A
4515637 Cioca May 1985 A
4522302 Paikoff Jun 1985 A
4536387 Sakamoto et al. Aug 1985 A
4540410 Wood et al. Sep 1985 A
4543332 Jao et al. Sep 1985 A
4554156 Fischer Nov 1985 A
4556156 Frutin Dec 1985 A
4559304 Kasai et al. Dec 1985 A
4600574 Lindner et al. Jul 1986 A
4640834 Eibl et al. Feb 1987 A
4655211 Sakamoto et al. Apr 1987 A
4685597 Hirao et al. Aug 1987 A
4696812 Silbering Sep 1987 A
4702737 Pizzino Oct 1987 A
4735616 Eibl et al. Apr 1988 A
4743229 Chu May 1988 A
4746514 Warne May 1988 A
4749689 Miyata et al. Jun 1988 A
4752466 Saferstein et al. Jun 1988 A
4803075 Wallace et al. Feb 1989 A
4818517 Kwee et al. Apr 1989 A
4832686 Anderson May 1989 A
4837285 Berg et al. Jun 1989 A
4851521 Della Valle et al. Jul 1989 A
4861714 Dean, Jr. et al. Aug 1989 A
4863856 Dean, Jr. et al. Sep 1989 A
4885161 Cornell Dec 1989 A
4887743 Blakesley et al. Dec 1989 A
4891359 Saferstein et al. Jan 1990 A
4920158 Murray et al. Apr 1990 A
4925677 Feijen May 1990 A
4936835 Haaga et al. Jun 1990 A
4946870 Partain, III et al. Aug 1990 A
4965203 Silbering et al. Oct 1990 A
4982769 Fournier et al. Jan 1991 A
4997753 Dean, Jr. et al. Mar 1991 A
5007916 Linsky et al. Apr 1991 A
5017229 Burns et al. May 1991 A
5023082 Friedman et al. Jun 1991 A
5024841 Chu et al. Jun 1991 A
5037740 Tanaka et al. Aug 1991 A
5041292 Feijen Aug 1991 A
5061274 Kensey Oct 1991 A
5061492 Okada et al. Oct 1991 A
5062834 Gross et al. Nov 1991 A
5080893 Goldberg et al. Jan 1992 A
5108421 Fowler Apr 1992 A
5112750 Tanaka et al. May 1992 A
5126141 Henry Jun 1992 A
5129882 Weldon et al. Jul 1992 A
5134229 Saferstein et al. Jul 1992 A
5135751 Henry et al. Aug 1992 A
5135755 Czech et al. Aug 1992 A
5140016 Goldberg et al. Aug 1992 A
5149540 Kunihiro et al. Sep 1992 A
5162430 Rhee et al. Nov 1992 A
5165938 Knighton Nov 1992 A
5178883 Knighton Jan 1993 A
5180583 Hedner Jan 1993 A
5192300 Fowler Mar 1993 A
5196185 Silver et al. Mar 1993 A
5204382 Wallace et al. Apr 1993 A
5209776 Bass et al. May 1993 A
5219328 Morse et al. Jun 1993 A
5275616 Fowler Jan 1994 A
5281528 Boctor et al. Jan 1994 A
5292362 Bass et al. Mar 1994 A
5300494 Brode, II et al. Apr 1994 A
5304377 Yamada et al. Apr 1994 A
5306501 Viegas et al. Apr 1994 A
5324775 Rhee et al. Jun 1994 A
5328955 Rhee et al. Jul 1994 A
5330446 Weldon et al. Jul 1994 A
5350573 Goldberg et al. Sep 1994 A
5350581 Kochinke Sep 1994 A
5352715 Wallace et al. Oct 1994 A
5356614 Sharma Oct 1994 A
5356883 Kuo et al. Oct 1994 A
5384333 Davis et al. Jan 1995 A
5385606 Kowanko Jan 1995 A
5387208 Ashton et al. Feb 1995 A
5394886 Nabai et al. Mar 1995 A
5397704 Boctor et al. Mar 1995 A
5399361 Song et al. Mar 1995 A
5401511 Margalit Mar 1995 A
5418222 Song et al. May 1995 A
5428022 Palefsky et al. Jun 1995 A
5428024 Chu et al. Jun 1995 A
5437672 Allyne Aug 1995 A
5441491 Verschoor et al. Aug 1995 A
5443481 Lee Aug 1995 A
5447966 Hermes et al. Sep 1995 A
5456693 Conston et al. Oct 1995 A
5462860 Mach Oct 1995 A
5478352 Fowler Dec 1995 A
5503848 Perbellini et al. Apr 1996 A
5507744 Tay et al. Apr 1996 A
5510418 Rhee et al. Apr 1996 A
5512301 Song et al. Apr 1996 A
5514379 Weissleder et al. May 1996 A
5516532 Atala et al. May 1996 A
5520925 Maser May 1996 A
5531759 Kensey et al. Jul 1996 A
5540715 Katsaros et al. Jul 1996 A
5580923 Yeung et al. Dec 1996 A
5595735 Saferstein et al. Jan 1997 A
5599735 Moslehi Feb 1997 A
5614587 Rhee et al. Mar 1997 A
5618551 Tardy et al. Apr 1997 A
5643596 Pruss et al. Jul 1997 A
5645849 Pruss et al. Jul 1997 A
5648506 Desai et al. Jul 1997 A
5658592 Tanihara et al. Aug 1997 A
5660854 Haynes et al. Aug 1997 A
5667839 Berg Sep 1997 A
5669934 Sawyer Sep 1997 A
5672336 Sharma Sep 1997 A
5674275 Tang et al. Oct 1997 A
5690675 Sawyer et al. Nov 1997 A
5690954 Ilium Nov 1997 A
5698213 Jamiolkowski et al. Dec 1997 A
5700476 Rosenthal et al. Dec 1997 A
5712161 Koezuka et al. Jan 1998 A
5714370 Eibl et al. Feb 1998 A
5723308 Mach et al. Mar 1998 A
5743312 Pfeifer et al. Apr 1998 A
5749895 Sawyer et al. May 1998 A
5752974 Rhee et al. May 1998 A
5770229 Tanihara et al. Jun 1998 A
5791352 Reich et al. Aug 1998 A
5795330 Tofighi et al. Aug 1998 A
5798091 Trevino et al. Aug 1998 A
5823671 Mitchell et al. Oct 1998 A
5824015 Sawyer Oct 1998 A
5853749 Hobbs Dec 1998 A
5856356 Tsouderos et al. Jan 1999 A
5861043 Carn Jan 1999 A
5874500 Rhee et al. Feb 1999 A
5876372 Grabenkort et al. Mar 1999 A
5883078 Seelich et al. Mar 1999 A
5890610 Jansen et al. Apr 1999 A
5895412 Tucker Apr 1999 A
5902832 Van Bladel et al. May 1999 A
5908054 Safabash et al. Jun 1999 A
5931165 Reich et al. Aug 1999 A
5939259 Harvey et al. Aug 1999 A
5951531 Ferdman et al. Sep 1999 A
5951583 Jensen et al. Sep 1999 A
5957166 Safabash Sep 1999 A
5959735 Maris et al. Sep 1999 A
5986168 Noishiki et al. Nov 1999 A
5997895 Narotam et al. Dec 1999 A
6007613 Izoret Dec 1999 A
6096309 Prior et al. Jan 2000 A
6027741 Cialdi et al. Feb 2000 A
6042262 Hajianpour Mar 2000 A
6045570 Epstein et al. Apr 2000 A
6063061 Wallace et al. May 2000 A
6066325 Wallace et al. May 2000 A
6074663 Delmottet et al. Jun 2000 A
6099952 Cercone Aug 2000 A
6110484 Sierra Aug 2000 A
6113948 Heath Sep 2000 A
6129761 Hubbell Oct 2000 A
6132759 Schacht et al. Oct 2000 A
6146587 Morgan Nov 2000 A
6162241 Coury et al. Dec 2000 A
6166130 Rhee et al. Dec 2000 A
6168788 Wortham Jan 2001 B1
6171276 Lippe Jan 2001 B1
6179872 Bell et al. Jan 2001 B1
6193670 Van Tassel Feb 2001 B1
6218176 Berthold et al. Apr 2001 B1
6224862 Turecek et al. May 2001 B1
6261596 Li et al. Jul 2001 B1
6277394 Sierra Aug 2001 B1
6280727 Prior et al. Aug 2001 B1
6283933 D'Aiessio et al. Sep 2001 B1
6300128 Morota et al. Oct 2001 B1
6303323 Laskey et al. Oct 2001 B1
6312474 Francis et al. Nov 2001 B1
6312725 Wallace et al. Nov 2001 B1
6321951 Frutin Nov 2001 B1
6328229 Duronio et al. Dec 2001 B1
6334865 Redmond et al. Jan 2002 B1
6361551 Torgerson et al. Mar 2002 B1
6364519 Ali Apr 2002 B1
6387413 Miyata et al. May 2002 B1
6391343 Yen May 2002 B1
6416739 Rogerson Jul 2002 B1
6423037 Hijikata et al. Jul 2002 B1
6454787 Maddalo et al. Sep 2002 B1
6458380 Leaderman Oct 2002 B1
6458386 Schacht et al. Oct 2002 B1
6458889 Trollsas Oct 2002 B1
6461325 Delmotte et al. Oct 2002 B1
6472162 Coelho Oct 2002 B1
6495127 Wallace et al. Dec 2002 B1
6548081 Sadozai et al. Apr 2003 B2
6584858 Miyazawa et al. Jul 2003 B1
6620436 Hughes et al. Sep 2003 B1
6635272 Leaderman Oct 2003 B2
6638538 Hashimoto et al. Oct 2003 B1
6649162 Biering et al. Nov 2003 B1
6706690 Reich et al. Mar 2004 B2
6716435 Farmer et al. Apr 2004 B1
6733774 Stimmeder May 2004 B2
6831058 Ikada et al. Dec 2004 B1
6861046 Appino et al. Mar 2005 B1
6887974 Pathak May 2005 B2
6902543 Cherif-Cheikh Jun 2005 B1
7052713 Stimmeder May 2006 B2
7056722 Coelho Jun 2006 B1
7109163 Pendharkar et al. Sep 2006 B2
7125860 Renier et al. Oct 2006 B1
7320962 Reich et al. Jan 2008 B2
7393674 Jiang et al. Jul 2008 B2
7427607 Suzuki Sep 2008 B2
7435425 Qian et al. Oct 2008 B2
7547446 Qian et al. Jun 2009 B2
7833965 Pendharkar et al. Nov 2010 B2
7871637 Qian et al. Jan 2011 B2
7927626 Pendharkar et al. Apr 2011 B2
7935371 Williams May 2011 B2
8071090 Senderoff et al. Dec 2011 B2
8119160 Looney et al. Feb 2012 B2
8303981 Wallace et al. Nov 2012 B2
8329119 Pearcy et al. Dec 2012 B2
8357378 Wallace et al. Jan 2013 B2
8512729 Wallace et al. Aug 2013 B2
8551941 Pendharkar et al. Oct 2013 B2
8556848 Klug et al. Oct 2013 B2
8603511 Wallace et al. Dec 2013 B2
8642831 Larsen et al. Feb 2014 B2
8846105 Koopman et al. Sep 2014 B2
9265858 Larsen Feb 2016 B2
9376674 Jorquera Nieto et al. Jun 2016 B2
9408945 Goessl et al. Aug 2016 B2
9533069 Larsen et al. Jan 2017 B2
9629798 Senderoff et al. Apr 2017 B2
9724078 Larsen et al. Aug 2017 B2
9999703 Larsen Jun 2018 B2
10111980 Larsen Oct 2018 B2
10595837 Larsen et al. Mar 2020 B2
10653837 Larsen May 2020 B2
10799611 Larsen Oct 2020 B2
10918796 Larsen Feb 2021 B2
20010008636 Yamamoto et al. Jul 2001 A1
20010038848 Donda Nov 2001 A1
20010041913 Cragg et al. Nov 2001 A1
20020006429 Redmond et al. Jan 2002 A1
20020010150 Cortese et al. Jan 2002 A1
20020010482 Watt et al. Jan 2002 A1
20020012982 Blakesley et al. Jan 2002 A1
20020015724 Yang et al. Feb 2002 A1
20020019062 Lea et al. Feb 2002 A1
20020025921 Petito et al. Feb 2002 A1
20020026215 Redmond et al. Feb 2002 A1
20020027146 de LaForcade et al. Mar 2002 A1
20020039594 Unger Apr 2002 A1
20020042378 Reich et al. Apr 2002 A1
20020061842 Mansour et al. May 2002 A1
20020072767 Zhu Jun 2002 A1
20020082620 Lee et al. Jun 2002 A1
20020111576 Greene et al. Aug 2002 A1
20020164322 Schaufler Nov 2002 A1
20020173818 Reever Nov 2002 A1
20020188196 Burbank et al. Dec 2002 A1
20020192271 Hedner et al. Dec 2002 A1
20020193448 Wallace et al. Dec 2002 A1
20030004449 Lafratta et al. Jan 2003 A1
20030008831 Yang et al. Jan 2003 A1
20030009194 Saker et al. Jan 2003 A1
20030012741 Furlan et al. Jan 2003 A1
20030028140 Greff Feb 2003 A1
20030032143 Neff et al. Feb 2003 A1
20030040701 Dalmose Feb 2003 A1
20030064109 Qian et al. Apr 2003 A1
20030095993 Benz et al. May 2003 A1
20030162708 Wolff Aug 2003 A1
20030175410 Campbell Sep 2003 A1
20030175419 Sessa Sep 2003 A1
20030181659 Naranda et al. Sep 2003 A1
20030224056 Kotha et al. Dec 2003 A1
20030232746 Lamberti et al. Dec 2003 A1
20040062790 Constantine Apr 2004 A1
20040076647 Ferrosan Apr 2004 A1
20040079763 Beiring Apr 2004 A1
20040101546 Gorman et al. May 2004 A1
20040120993 Zhang et al. Jun 2004 A1
20040186432 Barry et al. Sep 2004 A1
20040197388 Sceusa Oct 2004 A1
20040214770 Reich et al. Oct 2004 A1
20040243043 McCarthy et al. Dec 2004 A1
20040267352 Davidson et al. Dec 2004 A1
20050008632 Stimmeder Jan 2005 A1
20050031691 McGurk et al. Feb 2005 A1
20050137512 Campbell et al. Jun 2005 A1
20050171001 Pendharkar et al. Aug 2005 A1
20050186253 Lee et al. Aug 2005 A1
20050214277 Schaufler Sep 2005 A1
20050218541 Peng et al. Oct 2005 A1
20050239675 Makansi Oct 2005 A1
20050245905 Schmidt et al. Nov 2005 A1
20050284809 Looney et al. Dec 2005 A1
20060002890 Hersel et al. Jan 2006 A1
20060002918 Jiang et al. Jan 2006 A1
20060052747 Nishimura et al. Mar 2006 A1
20060067976 Ferraro et al. Mar 2006 A1
20060068013 DiTizio et al. Mar 2006 A1
20060115805 Hansen Jun 2006 A1
20060121080 Lye et al. Jun 2006 A1
20060121104 Stern Jun 2006 A1
20060147492 Hunter et al. Jul 2006 A1
20060159733 Pendharkar et al. Jul 2006 A1
20060167561 Odar et al. Jul 2006 A1
20060189516 Yang et al. Aug 2006 A1
20060193846 Stimmeder Aug 2006 A1
20060204490 Pendharkar et al. Sep 2006 A1
20060255053 Li Nov 2006 A1
20060282138 Ota Dec 2006 A1
20070009578 Moller Jan 2007 A1
20070025955 Lowinger et al. Feb 2007 A1
20070086958 Drake et al. Apr 2007 A1
20070128343 Chappa Jun 2007 A1
20070160543 Moiler Jul 2007 A1
20070217282 Lidgren et al. Sep 2007 A1
20070250007 Shekalim Oct 2007 A1
20070264130 Mallett Nov 2007 A1
20070264301 Cleek et al. Nov 2007 A1
20070264302 Cleek et al. Nov 2007 A1
20080029087 Kidd, III Feb 2008 A1
20080085316 Qian et al. Apr 2008 A1
20080091277 Deusch et al. Apr 2008 A1
20080095830 Van Holten Apr 2008 A1
20080109002 Delmotte May 2008 A1
20080199539 Baker et al. Aug 2008 A1
20080286376 Qian et al. Nov 2008 A1
20080311172 Schapira et al. Dec 2008 A1
20090087569 Fan et al. Feb 2009 A1
20090142396 Odar et al. Jun 2009 A1
20100028309 Odar et al. Feb 2010 A1
20100048758 Chen et al. Feb 2010 A1
20100063459 Preiss-Bloom et al. Mar 2010 A1
20100113828 Dalsin May 2010 A1
20100143447 Hansen Jun 2010 A1
20100256671 Falus Oct 2010 A1
20100292717 Petter-Puchner et al. Nov 2010 A1
20100318048 Hoeffinghoff et al. Dec 2010 A1
20110021964 Larsen Jan 2011 A1
20110045034 Nur et al. Feb 2011 A1
20110059228 Gillick et al. Mar 2011 A1
20110270167 Matusch Nov 2011 A1
20120128653 Goessl et al. May 2012 A1
20120201726 Pearcy et al. Aug 2012 A1
20130108671 McCoy May 2013 A1
20140220130 Larsen et al. Aug 2014 A1
20140369991 Schutte Dec 2014 A1
20150037314 Larsen Feb 2015 A1
20160120527 Larsen et al. May 2016 A1
20160354512 Larsen Dec 2016 A1
20170311939 Larsen et al. Nov 2017 A1
20180147355 Larsen May 2018 A1
20180243468 Larsen Aug 2018 A1
20180264194 Larsen Sep 2018 A1
20190015546 Larsen Jan 2019 A1
20200140625 Larsen May 2020 A1
Foreign Referenced Citations (205)
Number Date Country
0051589 Jul 1993 BG
0099900 Mar 1997 BG
1270240 Oct 2000 CN
3146841 Jun 1983 DE
4119140 Dec 1992 DE
4407875 Sep 1995 DE
0132983 Feb 1985 EP
0156649 Oct 1985 EP
0282316 Sep 1988 EP
0341007 Nov 1989 EP
0341745 Nov 1989 EP
0365705 May 1990 EP
0372966 Jun 1990 EP
0385916 Sep 1990 EP
0395758 Nov 1990 EP
0172710 Mar 1992 EP
0478827 Apr 1992 EP
0493387 Oct 1993 EP
0376931 Jun 1994 EP
0702081 Mar 1996 EP
0737467 Oct 1996 EP
0612252 May 1999 EP
0773740 Nov 1999 EP
1005874 Jun 2000 EP
1022031 Jul 2000 EP
1044693 Oct 2000 EP
1053758 Nov 2000 EP
1084720 Mar 2001 EP
1140235 Oct 2001 EP
1174463 Jan 2002 EP
1258256 Nov 2002 EP
1283063 Feb 2003 EP
0790823 Jul 2003 EP
0891193 Aug 2003 EP
1484070 Dec 2004 EP
1095064 Jun 2005 EP
1543842 Jun 2005 EP
1649867 Apr 2006 EP
1361906 Apr 2007 EP
1414370 Apr 2007 EP
1059957 Aug 2007 EP
1608230 Jul 2010 EP
2 040 724 Oct 2011 EP
2679772 May 1993 FR
2759980 Aug 1998 FR
648619 Jan 1951 GB
697603 Sep 1953 GB
1037937 Aug 1966 GB
1199887 Jul 1970 GB
1584080 Feb 1981 GB
1591654 Jun 1981 GB
2266239 Oct 1993 GB
2393120 Mar 2004 GB
2414021 Nov 2005 GB
51-125156 Nov 1976 JP
59-113889 Jun 1984 JP
60214728 Oct 1985 JP
62070318 Mar 1987 JP
62221357 Sep 1987 JP
01130519 May 1989 JP
05308969 Nov 1993 JP
06254148 Sep 1994 JP
08-024325 Jan 1996 JP
9-504719 May 1997 JP
2004002271 Jan 2004 JP
2004147959 May 2004 JP
2005239713 Sep 2005 JP
2006015144 Jan 2006 JP
2006-296896 Nov 2006 JP
07090241 Apr 2007 JP
2010228932 Oct 2010 JP
2011212182 Oct 2011 JP
910007847 Oct 1991 KR
100751046 Aug 2007 KR
WO 8301244 Apr 1983 WO
WO 8600912 Feb 1986 WO
WO 8902730 Apr 1989 WO
WO 9013320 Nov 1990 WO
WO 9221354 Dec 1992 WO
WO 9222252 Dec 1992 WO
WO 9306802 Apr 1993 WO
WO 9306855 Apr 1993 WO
WO 9310768 Jun 1993 WO
WO 9321908 Nov 1993 WO
WO 9408552 Apr 1994 WO
WO 9417840 Aug 1994 WO
WO 9427630 Dec 1994 WO
WO 9512371 May 1995 WO
WO 9515747 Jun 1995 WO
WO 9525748 Sep 1995 WO
WO 9531955 Nov 1995 WO
WO 9604025 Feb 1996 WO
WO 9606883 Mar 1996 WO
WO 9607472 Mar 1996 WO
WO 9610374 Apr 1996 WO
WO 9610428 Apr 1996 WO
WO 9612447 May 1996 WO
WO 9614368 May 1996 WO
WO 9616643 Jun 1996 WO
WO 9639159 Dec 1996 WO
WO 9640033 Dec 1996 WO
WO 9717023 May 1997 WO
WO 9717024 May 1997 WO
WO 9717025 May 1997 WO
WO 9729792 Aug 1997 WO
WO 9737694 Oct 1997 WO
WO 9808550 Mar 1998 WO
WO 9831403 Jul 1998 WO
WO 9834546 Aug 1998 WO
WO 9836784 Aug 1998 WO
WO 9843092 Oct 1998 WO
WO 9844963 Oct 1998 WO
WO 9851282 Nov 1998 WO
WO 9904828 Feb 1999 WO
WO 9912032 Mar 1999 WO
WO 9913902 Mar 1999 WO
WO 9938606 Aug 1999 WO
WO 9944901 Sep 1999 WO
WO 9945938 Sep 1999 WO
WO 99051208 Oct 1999 WO
WO 009018 Feb 2000 WO
WO 0018301 Apr 2000 WO
WO 0027327 May 2000 WO
WO 0061201 Oct 2000 WO
WO 0074742 Dec 2000 WO
WO 0076533 Dec 2000 WO
WO 0113956 Mar 2001 WO
WO 0128603 Apr 2001 WO
WO 0134206 May 2001 WO
WO 0154735 Aug 2001 WO
WO 0166161 Sep 2001 WO
0197871 Dec 2001 WO
WO 0197826 Dec 2001 WO
WO 0218450 Mar 2002 WO
WO 0222059 Mar 2002 WO
WO 0222184 Mar 2002 WO
WO 0240068 May 2002 WO
WO 02058749 Aug 2002 WO
WO 02064182 Aug 2002 WO
02072128 Sep 2002 WO
WO 02070594 Sep 2002 WO
2002096488 Dec 2002 WO
WO 03007845 Jan 2003 WO
WO 2003004072 Jan 2003 WO
WO 03024426 Mar 2003 WO
WO 03024429 Mar 2003 WO
WO 03055531 Jul 2003 WO
WO 03094983 Nov 2003 WO
WO 04028404 Apr 2004 WO
WO 04028423 Apr 2004 WO
WO 04029095 Apr 2004 WO
WO 04030711 Apr 2004 WO
WO 2004028583 Apr 2004 WO
WO 2004035629 Apr 2004 WO
WO 2004053051 Jun 2004 WO
WO 04075650 Sep 2004 WO
WO 04084869 Oct 2004 WO
WO 04108035 Dec 2004 WO
WO 2004108179 Dec 2004 WO
WO 2004108418 Dec 2004 WO
2005002510 Jan 2005 WO
WO 05000265 Jan 2005 WO
WO 05009225 Feb 2005 WO
WO 05041811 May 2005 WO
WO 05044285 May 2005 WO
WO 05062889 Jul 2005 WO
WO 2005063217 Jul 2005 WO
WO 2005072700 Aug 2005 WO
WO 2005084650 Sep 2005 WO
WO 05107713 Nov 2005 WO
WO 2006005340 Jan 2006 WO
WO 2006031358 Mar 2006 WO
WO 06034568 Apr 2006 WO
WO 06063758 Jun 2006 WO
WO 06128471 Dec 2006 WO
WO 2007001926 Jan 2007 WO
WO 2007018887 Feb 2007 WO
WO 2007092618 Aug 2007 WO
WO 2007133699 Nov 2007 WO
WO 2007137839 Dec 2007 WO
2008019127 Feb 2008 WO
WO 2008016983 Feb 2008 WO
2008060475 May 2008 WO
WO 2008051758 May 2008 WO
WO 2008090555 Jul 2008 WO
WO 2009020612 Feb 2009 WO
WO 2009109194 Sep 2009 WO
WO 2009109963 Sep 2009 WO
WO 2009131752 Oct 2009 WO
WO 2011047753 Apr 2011 WO
WO 2011151384 Dec 2011 WO
WO 2011151386 Dec 2011 WO
WO 2011151400 Dec 2011 WO
WO 2012146655 Nov 2012 WO
WO 2013053753 Apr 2013 WO
WO 2013053755 Apr 2013 WO
WO 2013053759 Apr 2013 WO
WO 2013060770 May 2013 WO
WO 2013185776 Dec 2013 WO
WO 2014086996 Jun 2014 WO
WO 20140202760 Dec 2014 WO
WO 2015086028 Jun 2015 WO
WO 2016058612 Apr 2016 WO
2017005590 Jan 2017 WO
WO 2017098493 Jun 2017 WO
Non-Patent Literature Citations (257)
Entry
FBC Industries Description of Sodium Lactate, accessed on May 31, 2018, http://www.fbcindustries.com/Sodium_Lactate.aspx.
Office Action for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Feb. 6, 2017.
Fiss, I., et al., “Use of Gelatin-Thrombin Hemostatic Sealant in Cranial Neurosurgery,” Neurologia Medico-Chirurgica, 47(10):462-467 (2007).
Mitsuhashi, J., “Invertebrate Tissue Culture Methods,” Springer Lab Manual, p. 407 (2002).
Oyelese, Yinka, et al., “Postpartum Hemhorrage,” Obstetrics and Gynecology Clinics of North America 34.3, 421-441 (2007).
Pschyrembel®—Klinisches Wörterbuch, 261st edition, de Gruyter (2007).
Sigma-Aldrich Datasheet for “Hank's Balanced Salts,” revised Apr. 2007.
Spotnitz, W. D., et al., “Hemostatus, Sealants, and Adhesives: Components of the Surgical Toolbox,” Transfusion, 48(7):1502-1516 (2008).
Stief, T. W., “Kallikrein Activates Prothrombin,” Clinical and Applied Thrombosis/Hemostasis, 14.1:97-98 (2008).
Non-Final Office Action for U.S. Appl. No. 14/516,728 dated Nov. 25, 2014 “Dry Haemostatic Composition”.
Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Feb. 26, 2015 “Dry Haemostatic Composition”.
Non-Final Office Action for U.S. Appl. No. 14/516,728, titled: “Dry Haemostatic Composition” dated Apr. 14, 2015.
Non-Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Oct. 2, 2014.
Notice of Allowance for U.S. Appl. No. 14/516,728, titled: “Dry Haemostatic Composition” dated Nov. 27, 2015.
Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Oct. 29, 2015 “Dry Haemostatic Composition”.
Notice of Allowance for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing” dated Sep. 23, 2016.
Romanelli, M., et al., “Exudate Management Made Easy”, downloaded from http://www.woundsinternational.com, 6 pgs., (Jan. 29, 2010).
Chronic Wound Care Guidelines © 2007 http://woundheal.org.documents/final_pocket_guide_treatment.aspx.
26th Annual Symposium: Clinical Update in Anaesthesiology, Surgery and Perioperative Medicine, Jan. 20-25, 2008.
Ansell, J., et al., “Gelfoam and Autologous Clot Embolization: Effect on Coagulation,” Investigative Radiology, 13: 115-120 (1978).
Arai, K., et al., “Clinical Effect of Thrombin-Collagen Sponge Sheet in Surgical Field,” Chiryo (Pharmacology and Treatment), 11(5):413-418 (1983). (English translation of Office Action for Japanese counterpart application 2010-547957, Title: Device for Promotion of Hemostasis and/or Wound Healing, being provided to satisfy “concise explanation” requirement under 37 C.F.R. 1.98(a)(3)).
Barrow, D.L., et al., “The Use of Greater Omentum Vascularized Free Flaps for Neurosurgical Disorders Requiring Reconstruction”, Journal of Neurosurgery, 60: 305-311 (1984).
Barton, B., et al., “Fibrin Glue as a Biologic Vascular Patch—A Comparative Study,” Journal of Surgical Research, vol. 40, 1 page; abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001. (1986).
Baxter, “GentaFleece Collagen Fleece—Version 5: Instructions for Use—Collagen Sponge with Antibiotic Protection for Surgical Use,” Retrieved from http://www.advancingbiosurgery.com/en_EU/downloads/ifu_gentaflecce.pdf on Mar. 2002, 2 pages. English portion second column of first page.
Baxter, “Product Catalogue: Collagen,” 4 pages, retrieved from http://www.baxter-ecommerce.com/ecatalog on Feb. 2, 2006 (2006).
Baxter, “TissuFleece E Package Leaflet,” Baxter International Inc., 4 pages, English portion of instructions for use (2003).
Baxter, “TissuFleece E, TissuCone E and TissuFoil E: Biomaterials,” Basic scientific Information, 9 pages (2003).
Boland, T., et al., “Application of Inkjet Printing to Tissue Engineering,” Biotechnol. J., 1:910-917 (2006).
Boyers, S., et al., “Reduction of Postoperative Pelvic Adhesions in the Rabbit with Gore-Tex Surgical Membrane”, Fertility and Sterility, 49(6,): 1066-1070 (1988).
Brannon-Peppas, L., et al., “The Equilibrium Swelling Behavior of Porous and Non-Porous Hydrogels,” Absorbent Polymer Technology, Elsevier, Amsterdam, pp. 67-102 (1990).
Branski, R.C., et al., “Mucosal Wound Healing in a Rabbit Model of Subglottic Stenosis”; Arch Otolaryngol Head Neck Surg, vol. 131, Feb. 2005, p. 153-157.
Campbell, P.G., et al., “Engineered Spatial Patterns of FGF-2 Immobilized on Fibrin Direct Cell Organization,” Biomaterials, 26: 6762-6770 (2005).
Campbell, P.G., et al., “Tissue Engineering with the Aid of Inkjet Printers,” Expert Opin. Biol. Ther., 7: 1123-1127 (2007).
Canal, T., et al., “Correlation Between Mesh Size and Equilibrium Degree of Swelling of Polymeric Networks” Biomedical Materials Research, 23: 1183-1193 (1989).
Cantor, M.O., et al., “Gelfoam® and Thrombin in treatment of massive gastroduodenal hemorrhage—A preliminary report”, American Journal of Surgery, 883-887 (Dec. 1950).
Cantor, M.O., et al., “Gelfoam and Thrombin in Gastroduodenal Bleeding: An Experimental Study,” Journal of Laboratory and Clinical Medicine, 35(6): 890-893 (1950).
Cantor, M.O., et al., “Gelfoam and Thrombin in Treatment of Massive Upper Gastrointestinal Hemorrhage,” American Journal of Surgery, 82(2): 230-235 (Aug. 1951).
Cascone, M.G., et al., “Collagen and hyaluronic acid based polymeric blends as drug delivery systems for the release of physiological concentrations of growth hormone.” Journal of Materials science: Materials in Medicine; 5: 770-774 (1994).
Changez, M., et al., Abstract of “Efficacy of antibiotics-loaded interpenetrating network (IPNs) hydrogel based on poly (acrylic acid) and gelatin for treatment of experimental osteomyelitis: in vivo study.”, Biomaterials; 26(14): 2095-2104 (2005).
Chaplin, J .M., et al., “Use of an Acellular Dermal Allograft for Dural Replacement: An Experimental Study,” Neurosurgery, 45(2): 320-327 (1999).
Cheung, D., et al., “Mechanism of Crosslinking of Proteins by Glutaraldehyde IV: In Vitro and In Vivo Stability of a Crosslinked Collagen Matrix,” Connective Tissue Research, 25: 27-34 (1990).
Choi, Y.S., et al., “Studies on Gelatin-Based Sponges. Part III: A Comparative Study of Cross-linked Gelatin/ Alginate, Gelatin/ Hyaluronate and Chitosan/Hyaluronate Sponges and their Application as a wound dressing in fullthickness skin defect of rat.”, J. of Mat. Sci.; Mat. in Med.; 12: 67-73 (Jan. 2001).
Choi, Y.S., et al., “Studies on gelatin-containing artificial skin: II. Preparation and characterization of cross-linked gelatin-hyaluronate sponge.”, J. Biomed Mater Res., 48: 631-639 (1999).
Christensen, F, et al., “Qualitative Description of the Wurster-Based Fluid-Bed Coating Process,” Drug Dev and Industry Pharmacy, 23(5): 451-463 (1977).
Chuang, V.P., et al., “Sheath Needle for Liver Biopsy in High-Risk Patients” Radiology, 166: 261-262 (1988).
Coenye, K.E., et al., “A Qualitative Morphological comparison of Two Heamostatic Agents in a Porcine Liver Trauma Model,” Surgical Science, 4: 359-364 (2013).
Collins, D., et al., “Enemata of Gelfoam Milk Suspension Combined with Thrombin-Solution to Control Massive Hemorrhage Following Anorectal Surgery,” The American Journal of Proctology, 2: 60-63 (1951).
Collins, R., et al., “Use of Collagen Film as a Dural Substitute: Preliminary Animal Studies,” Journal of Biomedical Materials Research, 25: 267-276 (1991).
De Iaco, P.A., et al., “Efficacy of a Hyaluronan Derivative gel in postsurgical adhesion prevention in the presence of inadequate hemostasis.” Surgery, 130(1): 60-64 (2001).
De la Torre, R.A., et al., “Hemostasis and Hemostatic agents in minimally invasive surgery”, Surgery, 142(4S): S39-S45 (2007).
DeLustro, F., et al., “A Comparative Study of the Biologic and Immunologic Response to Medical Devices Derived From Dermal Collagen,” Journal of Biomedical Materials Research, 20: 109-120 (1986).
Dembo, M.A., et al.; Abstract of “Antiseptic hemostatic preparations, their properties and study”, Lech. Prep. Krovi Tkanei; pp. 139-140 (1974).
Dodd, G.D., et al., “Minimally invasive treatment of malignant hepatic tumors. At the threshold of a major breakthrough”, Radiographies, 20: 9-27 (2000).
Drognitz, O., et al., Abstract of “Release of vancomycin and teicoplanin from a plasticized and resorbable gelatin sponge: in vitro investigation of a new antibiotic delivery system with glycopeptides”; lndection Germany (Minich); 34(1): 29-34 (2006).
Duchene, D., et al., “Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration,” Drug Dev and Industr Pharmacy, 14(2&3):283-318 (1988).
Edgerton, M., et al., “Vascular Hamatomas and Hemagiomas: Classification and Treatment,” Southern Medical Journal, 75(12): 1541-1547 (1982).
Ellegala, D.B., et al., “Use of FloSeal Hemostatic Sealant in Transsphenoidal Pituitary Surgery: Technical Note.”; Neurosurgery, 51: 513-516 (Aug. 2002).
Filippi, R., et al., “Bovine Pericardium for Duraplasty: Clinical Results in 32 Patients,” Neurological Review, 20:103-107 (2001).
Flory, P., “Phase Equilibria in Polymer Systems,” Principles of Polymer Chemistry, 13:541-594 (1953).
“Formulation and Evaluation of Absorbable Gelatin Sponges,” Chapter 3A of Rupali Kale thesis: Design and Development of Surgical Dressings for Advanced Wound Management (2010).
Fujii, Y., et al., “Safety of GT XIII (Report 2)—Japanese + English translation,” The Clinical Report, 20(17) (Dec. 1986).
Gall, R.M., “Control of Bleeding in Endoscopic Sinus Surgery: Use of a Novel Gelatin-Based Hemostatic Agent”, Journal of Otolaryngology, 31(5): (2002).
“Gelfoam Prescribing Information,” Pharmacia & Upjohn (Nov. 1996).
“Gelfoam® Product Brochure,” Pharmacia & Upjohn (Jun. 2013).
Gibble, J.W., et al., “Fibrin glue: the perfect operative sealant?” Reviews: Transfusion, 30(8): 741-747 (1990).
Guinto, F., “Preparation of Gelfoam Particles Using an Orthopedic Rasp,” Radiology, 153: 250 (1984).
Gurny, R., et al., “Bioadhesive Intraoral Release Systems: Design, Testing and Analysis,” Biomaterials, 5: 336-340 (1984).
Hae-Won, K., et al., Abstract of “Porus scaffolds of gelatin-hydroxyapatite nanocomposites obtained by biometic approach: Characterization and antibiotic drug release.”; J. of Biomedical Materials Research, 74B(2): 686-698 (2005).
Harris, W.H., et al., “Topical Hemostatic Agents for Bone Bleeding in Humans,” The Journal of Bone and Joint Surgery, 60-A(4): 454-456 (1978).
Heller, J., et al., “Release of Norethindrone from Poly(Ortho Esters),” Polymer Engineering and Science, 21: 727-731 (1981).
Herndon, J., et al., “Compression of the Brain and Spinal Cord Following Use of Gelfoam,” Arch. Surg, 104: 107 (Jan. 1972).
Hieb, L., et al, “Spontaneous Postoperative Cerebrospinal Fluid Leaks Following Application of Anti-Adhesion Barrier Gel,” Spine, 26(7): 748-751 (2001).
Hill, et al., “Use of microfibrillar collagen hemostat (avitenet) and thrombin to achieve hemostats after median sternotomy.”; J. Thorac Cardiovasc Surg., 108: 1151-1152 (1994).
Hill-West, J.L., et al., “Efficiacy of a resorbable hydrogel barrier, oxidized regenerated cellulose and hyaluronic acid in the prevention of ovarian adhesions in a rabbit model.”; Fertility and Sterility, 62(3): 630-634 (1994).
Hong, S.R., et al., Abstract of “Study on gelatin-containing artificial skin IV: a comparative study on the effect of antibiotic and EGF on cell proliferation during epidermal healing.”; Biomaterials, 22(20): 2777-2783 (2001).
Hong, Y.M., et al., “The Use of Hemostatic Agents and Sealants in Urology”, The Journal of Urology, 176: 2367-2374 (2006).
Hood, D., et al., “Efficacy of Topical Hemostat Floseal Matrix in Vascular Surgery,” 24th World Congress of the International Society for Cardiovascular Surgery, Sep. 12-16, 1999, 2 pages.
Hotz, G., et al., “Collagen and Fibrin as Biologic Binders from Granular Hydroxyapatite,” Deutsche Zeitschrift fur Mund-Kieferund Gesichts-Chirurgie, 13(4): 296-300 (1989). Abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001.
International Preliminary Examination Report for International Application No. PCT/DK03/00855, “Gelatine-Based Materials As Swabs”, completed Jun. 2, 2005.
International Preliminary Report on Patentability (Corrected Version) for International Application No. PCT/DK2005/000063, “Haemostatic Sprays and Compositions”, completed Nov. 6, 2006.
International Preliminary Report on Patentability for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, completed Aug. 16, 2006.
International Preliminary Report on Patentability for International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”, completed May 29, 2009.
International Preliminary Report on Patentability for International Application No. PCT/DK2009/050048, “Device for Promotion of Hemostasis and/or Wound Healing”, completed Sep. 6, 2010.
International Preliminary Report on Patentability for International Application No. PCT/DK2013/050054, “Pressurized Container Containing Haemostatic Paste”, dated Sep. 9, 2014.
International Preliminary Report on Patentability from counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Jul. 6, 2012.
International Search Report & Written Opinion of the International Searching Authority For International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”, dated Apr. 23, 2008.
International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Jun. 21, 2011.
International Search Report for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, dated Oct. 25, 2005.
International Search Report for International Application No. PCT/DK2013/050054, “Pressurized Container Containing Haemostatic Paste”, dated Sep. 10, 2013.
International Search Report for International Application No. PCT/DK2013/050191, “Dry Haemostatic Composition”, dated Aug. 21, 2013.
Jeong, B., et al., “Biodegradable Block Copolymers as Injectable Drug-Delivery Systems,” Nature, 388: 860-862 (1997).
Jonas, R., et al., “A new sealant for knitted Dacron prostheses: Minimally cross-linked gelatin,” Journal of Vascular Surgery, 7(3): 414-419 (1988).
Katayama, T., et al., “GT XIII safety (3rd report)—Japanese + English translation,” The Clinical Report, vol. 20 (1986).
Kelly M.J. et al., “The value of an operative wound swab sent in transport medium in the prediction of later clinical wound infection: A controlled clinical and bacteriological evaluation.”, Brit. J. Surgery, 65: 81-88 (1978).
Kim, K., et al., “Reduction in Leg Pain and Lower-Extremity Weakness with Oxiplex/SP Gel for 1 Year after Laminevtomy, Laminotomy, and Disectomy,” Neurosurgical Focus, 17: 1-6 (2004).
Kline, D., et al., “Dural Replacement with Resorbable Collagen,” Archives of Surgery, 91: 924-929 (1965).
Knopp, U., “A New Collagen Foil Versus a Cadaveric Dura Graft for Dural Defects—A Comparative Animal Experimental Study,” European Association of Neurosurgical Societies—Proceedings of the 12th European Congress of Neurosurgery, Lisbon, 17 pages (2003).
Koçak, I., et al., “Reduction of adhesion formation with cross-linked hyaluronic acid after peritoneal surgery in rats.”, Fertility and Sterility, 72(5): 873-878 (1999).
Kofidis, T., et al., “Clinically Established Hemostatis Scaffold (Tissue Fleece) as Biomatrix in Tissue and Organ Engineering Research,” Tissue Engineering, 9: 517-523 (2003).
Kost J., and Langer R., “Equilibrium Swollen Hydrogels in Controlled Release Applications,” Ch. 5: Hydrogels in Medicine and Pharmacy, vol. III: properties and Applications, N. Peppas ed., pp. 95-108 (1987).
Krill, D., et al., “Topical Thrombin and Powdered Gelfoam: An Efficient Hemostatic Treatment for Surgery,” Journal of Tennessee Dental Association, 66(2): 26-27 (1986).
Kuhn, J., et al., “Bilateral Subdural Heamatomata and Lumbar Pseudomeningocele Due to a Chronic Leakage of Liquor Cerebrospinalis after a Lumbar Disectomy with the Application of ADCON-L Gel,” Journal of Neurology, Neurosurgery & Psychiatry, 76: 1031-1033 (2005).
Langer, R., et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” Journal of Macromolecular Science—Reviews in Macromolecular Chemistry and Physics, C23: 61-126 (1983).
Laquerriere, A., et al., “Experimental Evaluation of Bilayered Human Collagen as a Dural Substitute,” Journal of Neurosurgery, 78: 487-491 (1993).
Larson, P., “Topical Hemostatic Agents for Dermatologic Surgery,” Journal of Dermatologic Surgery & Oncology, 14: 623-632 (1988).
Larsson, B., et al., “Surgicel®—an absorbable hemostatic material—in prevention of peritoneal adhesion in rats.”; Acta Chir Scand., 26(144): 375-378 (1978).
Laurent, C., et al., “Hyaluronic acid reduces connective tissue formation in middle ears filled with absorbable gelatin sponge: An experimental study.”, AM. J. Otolaryngol, 7: 181-186 (1986).
Le, A., et al., “Unrecognized Durotomy After Lumbar Discectomy: A Report of Four Cases Associated with the Use of ADCON-L,” Spine, 26(1): 115-118 (2001).
Lee, J., et al., “Experimental Evaluation of Silicone-Coated Dacron and Collagen Fabric-Film Laminate as Dural Substitutes,” Journal of Neurosurgery, 27: 558-564 (1967).
Lee, P., “Interpretation of Drug-Release Kinetics from Hydrogel Matrices in Terms of Time-Dependent Diffusion Coefficients,” Controlled-Release Technology—Pharmaceutical Applications, Ch. 5, ACS Symposium Series 348, pp. 71-83 (1986).
Leong, K., et al., “Polyanhydrides for Controlled Release of Bioactive Agents,” Biomaterials, 7: 364-371 (1986).
Leong, K., et al., “Polymeric Controlled Drug Delivery,” Advanced Drug Delivery Reviews, 1: 199-233 (1987).
Lewis, K., et al., “Comparison of Two Gelatin and Thrombin Combination Hemostats in a Porcine Liver Abrasion Model,” Journal of Investigative Surgery, 26: 141-148 (2013).
Li, G., et al., “Evaluation of esterified hyaluronic acid as middle ear-packing material.”, Arch Otolaryngol Head Neck Surg, 127: 534-539 (2001).
Loeb, J, “The Influence of Electrolytes Upon the Osmotic Pressure of Gelatin Solutions”, J. Biol. Chem., 35: 497-508 (1918).
Luengo, J., et al., “Prevention of peritoneal adhesions by the combined use of Spongostan and 32% Dextran 70: An experimental study in pigs.” Fertility and Sterility, 29(4): 447-450 (1978).
Masar, E., et al., “Synthesis of Polyurethanes and Investigation of their Hydrolytic Stability,” Journal of Polymer Science: Polymer Symposium, 66: 259-268 (1979).
Masuzawa, M., et al., “Experimental Study Related to the Hemostasis Action of GT XIII,” The Clinical Report, 20(2): 471-476 (Feb. 1986).
Matsumoto, K., et al., “A Gelatin Coated Collagen-Polyglycolic Acid Composite Membrane as a Dural Substitute,” American Society for Artificial Internal Organs Journal, 47: 641-645 (2001).
Maurer, P, et al., “Vicryl (Polyglactin 910) Mesh as a Dural Substitute,” Journal of Neurosurgery, 63:448-452 (1985).
Maxson, W.S., et al., “Efficacy of a modified oxidized cellulose fabric in the prevention of adhesion formation.” Gynecol. Obstet. Invest., 26: 160-165 (1988).
McClure, J., et al., “Massive Gastroduodenal Hemorrhage: Treatment with Powdered Gelfoam and Buffered Thrombin Solution,” Surgery, 32: 630-637 (1952).
McPherson, J., et al., “An Examination of the Biologic Response to Injectable, Glutaraldehyde Cross-linked Collagen Implants,” Journal of Biomedical Materials Research, 20: 93-107 (1986).
McPherson, J., et al., “Development and Biochemical Characterization of Injectable Collagen,” J. Dermatol. Surg. Oncol., 12(1): 13-20 (Jul. 7, 1988).
McPherson, J., et al., “The Effects of Heparin on the Physiochemical Properties of Reconstituted Collagen,” Collagen and Related Research, 1: 65-82 (1988).
McPherson, J., et al., “The Preparation and Physiochemical Characterization of an Injectable Form of Reconstituted, Glutaraldehyde Crosslinked, Bovine Corium Collagen,” Journal of Biomedical Materials Research, 20: 79-92 (1986).
Meddings, N., et al., “Collagen Vicryl—A New Dural Prosthesis,” Acta Neurochirurgica, 117: 53-58 (1992).
Mello, L., et al., “Duraplasty with Biosynthetic Cellulose: An Experimental Study,” Journal of Neurosurgery, 86: 143-150 (1997).
Miller, D., and Peppas, N., “Diffusional Effects During Albumin Adsorption on Highly Swollen Poly(vinyl Alcohol) Hydrogels,” Eur. Polym. J., 24(7): 611-615 (1988).
Miller, E.D., et al., “Dose-Dependent Cell Growth in Response to Concentration Modulated Patterns of FGF-2 Printed on Fibrin,” Biomaterials, 27: 2213-2221 (2006).
Millikan, L., “Treatment of Depressed Cutaneous Scars with Gelatin Matrix Implant: A Multicenter Study,” J. Am. Acad. Dermatol., 16: 1155-1162 (1987).
Min et al., “Molecular Weight Changes of Sodium Hyaluronate Powder and Solution by Heat treatment,” Matrix Biology Institute, Proceedings of Hyaluronan, Oct. 11-16, 2003.
Moak, E., “Hemostatic Agents: Adjuncts to Control Bleeding,” Today's O.R. Nurse, pp. 6-10 (1991).
Mueller, K., “Release and Delayed Release of Water-Soluble Drugs from Polymer Beads with Low Water Swelling,” Controlled-Release Technology—Pharmaceutical Applications, Ch. 11, ACS Symposium Series, 348: 139-157 (1986).
Narotam, P., et al., “A Clinicopathological Study of Collagen Sponge as a Dural Graft in Neurosurgery,” Journal of Neurosurgery, 82: 406-412 (1995).
Narotam, P., et al., “Experimental Evaluation of Collagen Sponge as a Dural Graft,” British Journal of Neurosurgery, 7: 635-641 (1993).
Nimni, M., et al., “Chemically Modified Collagen: A Natural Biomaterial for Tissue Replacement,” Journal of Biomedical Materials Research, 21: 741-771 (1987).
Nimni, M., Ph.D., “The Cross-Linking and Structure Modification of the Collagen Matrix in the Design of Cardiovascular Prosthesis,” Journal of Cardiac Surgery, 3: 523-533 (1988).
Nogueira, L., et al., Comparison of gelatine matrix-thrombin sealants used during laparoscopic partial nephrectomy, BJU International, 102: 1670-1674 (2008).
Novak, D., “Embolization Materials,” Interventional Radiology, pp. 295-313 (1990).
O'Neill, P., et al., “Use of Porcine Dermis as a Dural Substitute in 72 Patients,” Journal of Neurosurgery, 61: 351-354 (1984).
Ofner, C.M. and Bubnis, W.A., “Chemical and Swelling Evaluations of Amino Group Crosslinking in Gelatin and Modified Gelatin Matrices,” Pharma. Res., 13: 1821-1827 (1996).
Oz, M.C., et al., “Controlled clinical trial of a novel hemostatic agent in cardiac surgery.”, Ann Thorac Surg, 69: 1376-1382 (2000).
Oz, M.C., et al., “Floseal-Matrix: New Generation Topical Hemostatic Sealant”, J. Card. Surg., 18: 486-493 (2003).
Palm, S., et al., “Dural Closure with Nonpenetrating Clips Prevents Meningoneural Adhesions: An Experimental Study in Dogs,” Neurosurgery, 45(4): 875-882 (1999).
Parizek, J., et al., “Detailed Evaluation of 2959 Allogeneic and Xenogeneic Dense Connective Tissue Grafts (Fascia Lata, Pericardium, and Dura Mater) Used in the Course of 20 Years for Duraplasty in Neurosurgery,” Acta Neurochirurgica, 139: 827-838 (1997).
Park, Y-K., et al., “Prevention of Arachnoiditis and Postoperative Tethering of the Spinal Cord with Gore-Tex Surgical Membrane: An Experimental Study with Rats,” Neurosurgery, 42(4): 813-824 (1998).
Peppas, N. and Barr-Howell, B., “Characterization of the Cross-Linked Structure of Hydrogels,” Ch. 2: Hydrogels in Medicine and Pharmacy, vol. I. Fundamentals, N. Peppas ed., pp. 27-56 (1986).
Peppas, N. and Brannon-Peppas, L, “Hydrogels at Critical Conditions. Part 1. Thermodynamics and Swelling Behavior,” Journal of Membrane Science, 48: 281-290 (1990).
Peppas, N. and Khare, A., “Preparation, Structure and diffusional Behavior of Hydrogels in Controlled Release,” Adv. Drug Delivery Reviews, 11: 1-35 (1993).
Peppas, N. and Korsmeyer, R, “Dynamically Swelling Hydrogels in Controlled Release Applications,” Ch. 6: Hydrogels in Medicine and Pharmacy, vol. III: Properties and Applications, N. Peppas ed., pp. 109-135 (1987).
Peppas, N. and Lustig, S., “Solute Diffusion in Hydrophilic Network Structures,” Ch. 3: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 57-83 (1986).
Peppas, N. and Mikos, A., “Preparation Methods and Structure of Hydrogels,” Ch. 1: Hydrogels in Medicine and Pharmacy, vol. I. Fundamentals, N. Peppas ed., pp. 1-25 (1986).
Peppas, N. and Moynihan, H, “Structure and Physical Properties of Poly(2- Hydroxyethyl Methacrylate) Hydrogels,” Ch. 2: Hydrogels in Medicine and Pharmacy, vol. II: Polymers, N. Peppas ed., pp. 49-64 (1987).
Peppas, N., “Hydrogels and Drug Delivery,” Current Opinion in Colloid & Interface Science, 2: 531-537 (1997).
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 1. Fundamentals, CRC Press, Boca Raton, FL, 180 pages (1986).
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 2. Polymers, CRC Press, Boca Raton, FL, 172 pages (1987).
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 3. Properties and Applications, CRC Press, Boca Raton, FL, 196 pages (1987).
Peppas, N., “Hydrogels of Poly (Vinyl Alcohol) and its Copolymers,” Ch. 1: Hydrogels in Medicine and Pharmacy, vol. II: Polymers, N. Peppas ed., pp. 57 pgs (1987).
Peppas, N., ed., “Other Biomedical Applications of Hydrogels,” Ch. 9: Hydrogels in Medicine and Pharmacy, vol. III: Properties and Applications, pp. 177-186 (1987).
Pietrucha, K., “New Collagen Implant as Dural Substitute,” Biomaterials, 12: 320-323 (1991).
Pitt, C., et al., “Biodegradable Drug Delivery Systems Based on Aliphatic Polyesters: Application to Contraceptives and Narcotic Antagonists, ” Controlled Release of Bioactive Materials, R. Baker, ed., (NY: Academic Press) pp. 19-43 (1980).
Porchet, F., et al., “Inhibition of Epidural Fibrosis with ADCON-L: Effect on Clinical Outcome One Year Following Reoperation for Recurrent Lumbar Radiculopathy,” Neurological Research, 21: 551-560 (1999).
Product leaflet for FloSeal® Matrix Hemostatic Sealant dated Jul. 2001 (Jul. 2001).
Purdy, P.D., et al., “Microfibrillar collagen model of canine cerebral infarction”; Strokes, 20(10): 1361-1367 (Oct. 1989).
Quintavalla, J., et al., “Fluorescently labeled mesenchymal stem cells (MSCs) maintain mutlilineage potential and can be detected following implantation into Particular cartilage defects.”, Biomaterials, 23: 109-119 (2002).
Raftery, A., “Absorbable haemostatic materials and intraperitoneal adhesion formation.”; Br. J. Surg. 67; 1980; pp. 57-58.
Ratner, B., “Hydrogel Surfaces,” Ch. 4: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 85-94 (1986).
Raul, J.S., et al., “Utilisation du Polyester Urethane (NEUROPATCH) Comme Substitut Dural,” Neurochirugie, 49: 83-89, English abstract only on p. 83 (2003).
Reddy, M., et al., “A Clinical Study of a Fibrinogen-Based Collagen Fleece for Dural repair in Neurosergery,” Acta Neurochirurgica, 144: 265-269 (2002).
Reese, A.C., “Role of fibronectin in wound healing”, Report date: Sep. 12, 1986; Annual rept. Oct. 1, 1985-Mar. 31, 1986, Final rept. Oct. 1, 1983-Mar. 31, 1986. Corporate Author: Medical Coli of Gerogia Augusta Research Institute. Brunt and Klausner, “Growth factors speed wound healing”, Nature Biotechnology, 6(1): 25-30 (1988).
Reijnen, M.M.P.J., et al., “Prevention of intra-abdominal abscesses and adhesions using a hyaluronic acid solution in a rat peritonitis model.” Arch Surg. 134: 997-1001 (1999).
Renkens, K., et al, “A Multicenter, Prospective, Randomized Trial Evaluating a New Hemostatic Agent for Spinal Surgery,” Spine, 26(15): 1645-1650 (2001).
Riley, S., et al. “Percutaneous Liver Biopsy with Plugging of Needle Track: A Safe Method for Use in Patients with Impaired Coagulation,” Lancet, p. 436 (1984).
Roda, A., et al., “Protein Microdeposition Using a Conventional Ink-Jet Printer,” BioTechniques, 28(3): 492-496 (2000).
Rosenblatt, J., et al., “Effect of Electrostatic Forces on the Dynamic Rheological Properties of Injectable Collagen Biomaterials,” Biomaterials, 13: 878-886 (1982).
Rosenblatt, J., et al., “Injectable Collagen as a pHSensitive Hydrogel,” Biomaterials, 12: 985-995 (1984).
Ross, J., et al., “Association Between Peridural Scar and Recurrent Radicular Pain After Lumbar Discectomy: Magnetic Resonance Evaluation,” Neurosurgery, pp. 855-863 (1996).
Rossler, B., et al., “Collagen Microparticles: Preparation and Properties,” Journal of Microencapsulation, 12: 49-57 (1995).
Sakurabayashi, S., et al., “Clinical evaluation of new hemostatic agent for hemostasis from biopsy wounds in the liver.”; Gastroenterological Endoscopy 30:(10) 29 pgs. (Oct. 1988).
Sanfilippo, J.S., et al., “Comparison of avitene, topical thrombin and Gelfoam as sole hemostatic agent in tuboplasties.”, Fertility and Sterility, 33(3): 311-316 (1980).
San-Galli, F., et al., “Experimental Evaluation of a Collagen-Coated Vicryl Mesh as a Dural Substitute,” Neurosurgery, 30: 396-401 (1992).
Santomaso, A., et al., “Powder flowability and density rations: the impact of granules packing”, Chemical Engineering Science, 58: 2857-2874 (2003).
Schramm, V., et al., “Gelfoam Paste Injection for Vocal Cord Paralysis,” The Laryngoscope, 88: 1268-73 (1978).
Shaffrey, C.I., et al., “Neurosurgical Applications of Fibrin Glue: Augmentation of Dural Closure in 134 Patients,” Neurosurgery, 26: 207-210 (1990).
Shushan, A., et al., “Hyaluronic acid for preventing experimental postoperative intraperitoneal adhesions.”, Journal of Reproductive Medicine, 39(5): 398-402 (1994).
Shuxian, M. and Zhili, C., “Clinical Observation of the Treatment of Hemoptysis by Ultrasonic Atomizing Inhalation of Thrombin”, Chinese Journal of Critical Care Medicine, 16(2): 30 (1996).
Sidman, K., et al., “Biodegradable, Implantable Sustained Release Systems Based on Glutamic Acid Copolymers,” Journal of Membrane Science, 7: 227-291 (1979).
Simamora, P., et al., “Controlled delivery of pilocarpine. 2. In-vivo evaluation of Gelfoam® device,” International Journal of Pharmaceutics, 170(2): 209-214 (1998).
Smith, A., “New and Nonofficial Remedies: Absorbable Gelatin Sponge—Gelfoam-Upjohn,” Council on Pharmacy and Chemistry, 135(14): p. 921 (1947).
Smith, K., et al., “Delayed Postoperative Tethering of the Cervical Spinal Cord,” Journal of Neurosurgery, 81: 196-201 (1994).
Soules , M.R., et al., “The prevention of postoperative pelvic adhesions: An animal study comparing barrier methods with Dextran 70.”, Am. J. Obstet. Gynecol., 143(7): 829-834 (1982).
Spence et al., “Cerebellar capillary hemangioblastoma: its histogenesis studied by organ culture and electron microscopy.”, Cancer, 35(2): 326-341 (Feb. 1975).
Springorum, H., “Die Verwendung von Kollagenfolien Zur Uberbruckung von Defekten des Gleitgewebes bei Achillotenotomien und Achillessehnenrupturen,” Akt. Traumatol., 15: 120-121, English abstract only on p. 120 (1985).
Stricker, A., et al., “Die Verwendung von TissuFoil Membran bei der Sinusbodenaugmentation,” Ellipse, 17: 1-5 (2001). English abstract only on p. 1.
Sugitachi, A., et al., “A Newly Devised Chemo-Embolic Agent, G.T. XIIIADM,” Gan. To. Kagaku Ryoho, 12: 1942-1943 (1985). English abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 2, 2001.
Sugitachi, A., et al., “Locoregional Therapy in Patients with Malignant Pleural Effusion—Two Different Kinds of ‘BAC Therapy’,” Gan. To. Kagaku Ryoho, 19: 1640-1643 (1992). English abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001.
Sugitachi, A., et al., “Preoperative Transcatheter Arterial Chemo-Embolization for Locally Advanced Breast Cancer: Application for New Thrombotic Materials.” Japanese Journal of Surgery, 13: 456-458 (1992).
Surgiflo® Essential Prescribing Information, Hemostatic Matrix (Made from Absorbable Gelatin Sponge, U.S.P.), 1 page (2005).
Surgiflo® haemostatic matrix FlexTip, MS0009, 84 pages (2007).
Surgiflo® Prescription Information, Hemostatic Matrix, (Made from Surgifoam* Absorbable Gelatin Sponge U.S.P.) plus FlexTip, 2 pages (2008).
Surgiflo® product leaflet, “Surgiflo® Hemostatic Matrix Kit,” 5 pages (2012).
Surgiflo® product leaflet, “Surgiflo® Hemostatic Matrix,” 12 pages (2009).
Swann, D.A.,“Studies on hyaluronic acid—I. The preparation and properties of rooster comb hyaluronic acid”, Biochemica et biophysica acta, 156: 17-30 (1968).
Taheri, Z., “The Use of Gelfoam Paste in Anterior Cervical Fusion,” Journal of Neurosurgery, 34: 438 (1971).
Tobin, M., et al., “Plugged Liver Biopsy in Patients with Impaired Coagulation,” Digestive Diseases and Science, 34: 13-15 (1989).
Tucker, H., “Absorbable Gelatin (Gelfoam) Sponge,” Springfield, Illinois, Charles T. Thomas, pp. 3-125 (1965).
Van den Bosch, E., et al., “Gelatin degradation at elevated temperature”, International Journal of Biological Macromolecules, 32: 129-138 (2003).
Vandelli, M.A., et al., “The effect of the crosslinking time period upon the drug release and the dynamic swelling of gelatin microspheres,” Pharmazie, 46: 866-869 (1991).
Vander-Salm, T.J., et al., Abstract of “Reduction of sternal infection by application of topical vancomycin.”, J. of Thoracic and Cardiovascular Surgery, 98(4): 618-622 (1989).
Verhoeven, A.G., et al., “XV. The use of microporous polymeric powders for controlled release drug delivery systems,” Controlled Drug Delivery. Ch. 15, International Symposium of the Association for Pharmaceutical Technology (APV), Bad Homburg, Nov. 12-14, 1984, pp. 226-237.
Vinas, F., et al., “Evaluation of Expanded Polytetrafluoroethylene (ePTFE) versus Polydioxanone (PDS) for the Repair of Dura Mater Defects,” Neurological Research, 21: 262-268 (1999).
Wachoi-Drewek, Z., et al., “Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin.”, Biomaterials, 17: 1733-1738 (1996).
Wallace, D., “The Relative Contribution of Electrostatic Interactions to Stabilization of Collagen Fibrils,” Biopolymers, 29: 1015-1026 (1990).
Wallace, D., et al., “Injectable Cross-Linked Collagen with Improved Flow Properties,” Journal of Biomedical Materials Research, 23: 931-945 (1989).
Warren, W., et al., “Dural Repair Using Acellular Human Dermis: Experience with 200 Cases: Technique Assessment,” Neurosurgery, 46: 1391-1396 (2000).
Wassersug, J.D., M.D., “Use of Human Thrombin in Some Cases of Pulmonary Hemorrhage” Pulmonary Hemorrhage, vol. XVII, pp. 354-356 (Mar. 1950).
Weeks, R., “Microscopy of Soft Materials,” Chapter 1 in Experimental and Computational Techniques in Soft Condensed Matter Physics, Jeffrey Olafsen, Ed, 2010 (2010).
West et al., “Efficacy of adhesion barriers: Resorbable hydrogel, oxidized regenerated cellulose and hyaluronic acid.”, The Journal of Reproductive Medicine, 41(3) 149-154 (1996).
Wiesenthal, A.A., et al., Abstract of “New method for packing the external auditory canal, middle ear space, and mastoid cavities after otologic surgery”, The Journal of Otolaryngology; 28(5): 260-265 (1999).
Wilkinson, H., et al., “Gelfoam Paste in Experimental Laminectomy and Cranial Trephination,” Journal of Neurosurgery, 54: 664-667 (1981).
Written Opinion of the International Preliminary Examining Authority for counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Mar. 23, 2012.
Written Opinion of the International Searching Authority (Corrected Version) for International Application No. PCT/DK2005/000063, “Haemostatic Sprays and Compositions”, dated Jul. 26, 2005.
Written Opinion of the International Searching Authority for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, dated Oct. 24, 2005.
Written Opinion of the International Searching Authority for International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”.
Wu, Y. et al., Abstract of “Design and experimental study of a slow-release antibiotic membrane implant in surgery wound.”, Intern. Des Services de San. Des Forces Armees; 72(7-9): 194-196 (Sep. 1999).
Xing, Q., et al., “Increasing Mechanical Strength of Gelatin Hydrogels by Divalent Metal Ion Removal”, Sci. Rep., 4: 4706: DOI:10.1038/srep04706(2014).
Xu, T., et al., “Viability and electrophysiology of neural cell structures generated by the inkjet printing method”, Biomaterials, 27: 3580-3588 (2006).
Xu, T., et al., “Inkjet Printing of Viable Mammalian Cells,” Biomaterials, 26: 93-99 (2005).
Yaping, G., “Observation and Nursing of the Treatment of Hemoptysis of Pulmonary Tuberculosis by Ultrasonic Atomizing Inhalation of Thrombin”, Journal of Qilu Nursing, 10(2): 126 (Feb. 2004).
Youwen, W. et al., “Clinical Observation of the Therapeutic Efficacy of the Treatment of 15 Patients with Hemoptysis by Ultrasonic Atomizing Inhalation of Thrombin”, Chengdu Medical Journal, 30(5): 262 (Oct. 2004).
Yuki, N., et al., “Effects of Endoscopic Variceal Sclerotherapy Using GT XIII on Blood Coagulation Tests and the Renal Kallikrein-Kinin System,” Gastroentral. Japan, 25: 561-567 (1990). English abstract retrieved from http://www.ncbi.nlm.nih.gov Jan. 2, 2001.
Ziegelaar, B., et al., “The Characterisation of Human Respiratory Epithelial Cells Cultured on Resorbable Scaffords: First Steps Towards a Tissue Engineered Tracheal Replacement,” Biomaterials, 23: 1425-1438 (2002).
Ziegelaar, B., et al., “Tissue Engineering of a Tracheal Equivalent, Doctoral Thesis,” Munich, Germany, Ludwig Maximilians University, 2004, 25 pages (2004).
Zins, M., et al., “US-Guided Percutaneous Liver Biopsy with Plugging of the Needle Track: A Prospective Study in 72 High-Risk Patients,” Radiology, 184: 841-843 (1992).
Muranyi, A., et al., “Development of gel-forming lyophilized formulation with recombinant human thrombin”, Drug Development and Industrial Pharmacy 41(9): 1566-1573 (2015) (Abstract Only).
Notice of Allowance for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated May 30, 2017.
Notice of Allowability for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Jun. 12, 2017.
Notice of Allowance for U.S. Appl. No. 14/980,254, titled: “Dry Haemostatic Composition”, dated Jan. 24, 2018.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/EP2016/065260, “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Oct. 4, 2016.
Office Action for U.S. Appl. No. 15/102,994, titled: “Dry Composition Comprising an Extrusion Enhancer”, dated Feb. 22, 2018.
International Preliminary Report on Patentability for International Application No. PCT/EP2016/065260, “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, date of completion Dec. 6, 2017.
Notice of Allowability for U.S. Appl. No. 14/980,254, titled: “Dry Haemostatic Composition”, dated Feb. 13, 2018.
Schreiber, M.A., et al., “Achieving Hemostasis with Topical Hemostats: Making Clinically and Economically Appropriate Decisions in the Surgical and Trauma Settings”, AORN Journal, 94(5): S1-S20 (2011).
Office Action for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated May 8, 2019.
Notice of Allowance for U.S. Appl. No. 15/534,801, “Syringe for Retaining and Mixing First and Second Substances”, dated Jul. 25, 2019.
Office Action for U.S. Appl. No. 15/580,181, titled: “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Aug. 23, 2019.
Notice of Allowance for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Nov. 27, 2019.
Final Office Action for U.S. Appl. No. 15/580,181, titled: “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Jan. 7, 2020.
Notice of Allowance for U.S. Appl. No. 15/534,801, titled: “Syringe for Retaining and Mixing First and Second Substances”, dated Jan. 16, 2020.
Office Action for U.S. Appl. No. 15/513,780, “Dry Composition for Use in Haemostasis and Wound Healing” dated Apr. 9, 2020.
Office Action for U.S. Appl. No. 15/963,795, titled: “Dry Haemostatic Composition ”, dated Feb. 20, 2020.
Notice of Allowance for U.S. Appl. No. 15/963,795, titled: “Dry Haemostatic Composition ”, dated Jul. 30, 2020, 2020.
Final Office Action for U.S. Appl. No. 15/513,780, “Dry Composition for Use in Haemostasis and Wound Healing” dated Oct. 16, 2020.
Notice of Allowance for U.S. Appl. No. 15/580,181, titled: “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Oct. 1, 2020.
Office Action for U.S. Appl. No. 16/129,334, “Dry Composition Comprising an Extrusion Enhancer” dated Dec. 17, 2020.
Notice of Allowance for U.S. Appl. No. 15/513,780 “Dry Composition for Use in Haemostasis and Wound Healing” dated Feb. 23, 2021.
Related Publications (1)
Number Date Country
20150045830 A1 Feb 2015 US